A specialist revisits menopause hormone therapy timing. Learn how symptom goals, health history and sexual concerns fit an individual discussion.
On October 10, 2026, Seoul Economic Daily published a report in which menopause specialist Yoo Eun-hee reiterated timing guidance for hormone therapy. Yoo is a professor of obstetrics and gynecology at Kyung Hee University Hospital at Gangdong. Her message paired a generally favorable benefit-risk balance for symptom treatment within a timing window with assessment of each person's health and risks.
For readers weighing menopause symptoms against worries about treatment, the useful update is a clearer decision framework. The report describes age and time since menopause as considerations alongside symptoms and personal health. For a sexual-wellness audience, the starting point is understanding that framework before deciding which concerns to bring into a clinical conversation.
The report drew on Yoo's discussion of menopause symptoms and treatment on Seoul Economic Daily's television program “Jigeum Myeongui” (“Top Doctors Now”). Its scope included hormone therapy and health care after menopause.
The relevant population is women considering treatment for menopausal symptoms. The evidence presented here is reported expert guidance rather than results from a newly conducted experiment. There is no recruited study sample or trial follow-up period attached to this update.
The durations mentioned in the report concern symptoms and ongoing treatment. They are not observation periods for a new group of research participants. Understanding that distinction keeps the article's timing advice separate from a claim that a new study has measured treatment outcomes.
The central question is how symptom treatment should be considered in context. That context includes the person's stage of menopause and the health information needed for an individual decision. It is not simply a discussion of whether hormones are good or bad in the abstract.
According to Seoul Economic Daily, Yoo considers the benefit-risk balance generally favorable when hormone therapy for menopausal symptoms begins before age 60 or within 10 years of menopause. The purpose stated in the report is treatment of symptoms.
The word or matters. The reported guidance names alternative timing criteria rather than requiring readers to silently replace them with an “and.” Yoo also emphasized reviewing symptom severity and personal health when considering treatment.
The report lists hot flashes and night sweats alongside sleep disruption. Anxiety, depression and irritability are also included among symptoms that may prompt evaluation. It says more than half of women in the menopausal transition report sleep problems.
Seoul Economic Daily also reports that hot flashes and sweating average four to seven years. Some women experience them for more than a decade. These figures describe the reported course of symptoms rather than a recommended length of treatment.
This gives the timing discussion an everyday setting. The report is concerned with symptoms people may be living with over time, not just a date on a calendar or a single laboratory result.
The article describes combined estrogen and progesterone therapy as generally used for women with a uterus. Estrogen-only therapy may be used for women without one. This is one reason its discussion of hormone therapy involves different regimens rather than one uniform treatment.
The report also describes non-hormonal options that may be considered when hormone therapy cannot be used. It mentions antidepressants and gabapentin-class medicines. These are reported alternatives within a clinical discussion, not treatment choices for readers to make from the article.
According to the report, decisions about continuing hormone therapy after five years should be made jointly with a clinician. Benefits and risks should be reassessed annually. The discussion does not set a universal instruction to stop at five years.
For related educational background, Sexential's coverage of midlife hormone treatment questions places treatment discussions alongside broader sexual-health concerns.
The timing window is a population-level framework. It does not mean treatment is suitable for every person within it or that age alone settles the decision. Yoo's reported advice specifically includes individual health and risk assessment.
Seoul Economic Daily names circumstances that may restrict hormone therapy:
These are clinical considerations rather than a self-screening tool. Their significance belongs in an assessment with a qualified clinician.
The report also includes a breast-cancer risk statement that requires narrow reading. Yoo was reported as saying that combined therapy used for five years or longer was associated with fewer than one additional breast-cancer case per 1,000 women per year.
That figure belongs to the article's description of combined therapy and that duration. It should not be transferred to estrogen-only therapy or other formulations. It is also not an estimate of any individual reader's risk.
The article's account of earlier research is contextual rather than a complete review of the evidence. Its discussion of the Women's Health Initiative should be read on that basis.
Finally, the news report does not discuss libido, arousal, vaginal dryness or pain during sex. It therefore provides menopause-care context rather than evidence of a specific sexual-function benefit.
Seoul Economic Daily places Yoo's comments against concerns that followed the 2002 Women's Health Initiative study. The article reports that participants averaged about 63 years old. It uses that history to explain the background to treatment concerns and current discussion of timing.
The useful comparison is between a broad fear of hormone therapy and the more specific questions raised in Yoo's account. Those questions concern why treatment is being considered and how the person's circumstances enter the decision. The report presents timing as part of that discussion.
A separate Irish Pharmacy Union pharmacist's guide supports a similar individualized approach. It describes menopause care as shaped by symptoms and medical history. Risk factors and patient preferences also belong in the discussion of different hormone-therapy regimens.
The guide has a broader symptom scope than the news report. It identifies low libido and vaginal dryness among sexual difficulties that can occur around menopause. It recommends individualized management rather than treating every symptom as the same problem.
Read together, the sources support a distinction between a general treatment framework and a person's full set of concerns. Sexential's discussion of sexual wellbeing across menopause offers a related educational starting point for that wider conversation.
Yoo's reported advice supports seeking evaluation when symptoms affect everyday life. She characterized menopause as a natural life stage that need not simply be endured. An assessment can begin with what is happening and what has become difficult, rather than with a decision already made about treatment.
Readers can bring their symptoms and medical history into that discussion. Concerns about treatment risks matter too. The report's emphasis is on reviewing those details together rather than making a decision from age alone.
A written note can help organize the conversation around the information these sources identify as relevant: symptoms and their impact alongside health history and treatment concerns. It need not turn the appointment into a request for one particular medication.
The sources support discussing benefits and risks with a clinician. Questions that fit that approach include:
These questions keep attention on the treatment goal. They also make room for patient preferences, which the Irish Pharmacy Union guide explicitly includes in individualized care. Being worried about treatment and wanting relief are both concerns worth explaining.
The timing guidance is most useful as a reason to ask informed questions. Personal decisions about starting or continuing therapy belong with a qualified clinician who can assess the relevant history and risks.
The pharmacist's guide supports raising sexual difficulties directly. A conversation about hot flashes does not have to stand in for a conversation about desire or physical comfort. Naming the concern gives the clinician a clearer account of what the person wants assessed.
It can help to distinguish the concern itself from an assumed explanation. A change in desire is something to describe, not a conclusion about its cause. Sexential's background on questions surrounding libido and hormone testing provides another educational route into that discussion.
For single and partnered readers alike, intimate concerns deserve respectful language. There is no need to turn a symptom discussion into a judgment about effort or commitment. The aim is a clearer account of the experience and a more informed conversation about care.
Clear questions belong in menopause care. There is no shame in asking them.
Sorting menopause timing advice into questions for a clinical consultation is where Sexential's educational role begins. The publication addresses uncertainty about sexual function and its influences for readers aged 35 to 65 through measured explanations of hormones, aging and intimacy without diagnosing readers or recommending individual treatment.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A report on a student survey links attention with men’s sexual satisfaction. Here’s the evidence, its limits and the practical context for midlife.
A new report puts men’s midlife testosterone changes in context, with guidance on assessment, partner conversations and fertility considerations.
The Menopause Society’s 2026 program places lifestyle, sleep and sexual health together. Here is what the agenda and partner research actually report.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
